Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Color Diagnostics, |
RCV001180397 | SCV001345324 | uncertain significance | Hereditary cancer-predisposing syndrome | 2018-11-21 | criteria provided, single submitter | clinical testing | |
Invitae | RCV001312745 | SCV001503210 | uncertain significance | Li-Fraumeni syndrome | 2020-09-23 | criteria provided, single submitter | clinical testing | Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site, but this prediction has not been confirmed by published transcriptional studies. This variant has not been reported in the literature in individuals with TP53-related conditions. ClinVar contains an entry for this variant (Variation ID: 921142). This variant is not present in population databases (ExAC no frequency). This sequence change replaces threonine with serine at codon 231 of the TP53 protein (p.Thr231Ser). The threonine residue is highly conserved and there is a small physicochemical difference between threonine and serine. Experimental studies have shown that this variant does not substantially affect TP53 protein function (PMID: 12826609, 29979965). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Genome- |
RCV001180397 | SCV002582019 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-06-18 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV002290617 | SCV002582146 | uncertain significance | Li-Fraumeni syndrome 1 | 2022-06-18 | criteria provided, single submitter | clinical testing |